secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001636282-25-000022
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre reports Q4 2024 net loss of $56.3M; cash $603M; pipeline on track with Phase 2 trials in 2025
--------------------------------------------------------------------------------

- Cash, cash equivalents, and marketable securities $603.1M as of Dec 31, 2024; cash runway into H2 2028.
- Raised $230M in November 2024 public offering; Q4 net cash used in operations $37.2M.
- Interim Phase 1 data for SPY001 (α4β7) shows half-life >90 days supporting Q6M dosing; Phase 2 UC trial mid-2025.
- SPY002 (TL1A) Phase 1 interim data expected Q2 2025; Phase 2 RA trial initiation mid-2025; top-line 2026.
- SPY003 (IL-23) FIH trial starts Q1 2025 with interim data H2 2025; Phase 2 platform trial mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000163628225000022/0001636282-25-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000163628225000022/syre-20250227.htm
  HTML page:      https://secwatch.observer/filing/0001636282-25-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer